Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $912.33M
- Beta
- 0.00
Volume 0.37M
Average 0.43M
ODTX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Selling, General & Admin history
Currency unavailable · from the income statement
No Selling, General & Admin data reported for this period type.
Selling, General & Admin vs competitors
How ODTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $77.08M USD | +17.2% | +94.2% | 1041.9% |
| LTM Mar 2026 | $62.81M USD | +42.2% | +11.5% | 27.0% | |
| LTM Sep 2026 | $60.45M USD | +31.0% | +18.9% | 66.8% | |
| LTM Jun 2026 | $48.49M USD | +17.1% | +12.2% | 17.2% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $29.26M USD | +41.9% | +59.4% | — |
| LTM Mar 2026 | $23.53M USD | +30.1% | +11.7% | — | |
| LTM Mar 2026 | $22.58M USD | +5.5% | -4.4% | 269.8% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €9.82M EUR | +63.8% | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ODTX) | — | +30.5% | +12.2% | 66.8% | |
Competitors are the stored peer set for ODTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$18.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.